http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
김수성,조재훈,이학승,박현영,장혁,김요식,조광호 원광대학교 의과학연구소 2009 圓光醫科學 Vol.24 No.1
항응고제 치료의 주된 합병증은 출혈로서 주로 뇌실질과 복강 내에 발생하며 사지 근육에 발생하는 근육내 혈종은 매우 드문 것으로 알려져 있다. 이러한 항응고제 치료 후 발생하는 자발성 근육내 혈종은 발생빈도가 드물 뿐 아니라, 심부정맥혈전증과 그 증상이 유사하여 감별하기가 쉽지 않다. 저자들은 항응고제 치료 후 운동 마비가 발생한 사지 근육에서 자발성 근육내 혈종이 발생한 증례를 경험하여 이를 보고한다. Spontaneous intramuscular hematoma(SIH) is an uncommon but serious bleeding complication of anticoagulation therapy that has received little attention. We present a patient of spontaneous muscular hematoma during anticoagulation therapy for acute stroke management. A-74-year old man was admitted with sudden onset of dysarthria and left hemiparesis. Brain MRI and MRA showed acute cerebral infarction along right middle cerebral artery territory and severe stenosis of right proximal cervical internal carotid artery. During intravenous heparin treatment, he complained acute pain and swelling on left leg. Muscular CT showed enhancing focal soft tissue mass on left gastrocnemius muscle and ultrasonography demonstrated multiple hematomas on left gastrocnemius muscle. Treatment of heparin was stopped immediately. After conservative management for hematomas, symptoms were subsided.
( Seung Kak Shin ),( Young Kul Jung ),( Seung Jun Jang ),( Hae Lim Baek ),( Hyun Hwa Yoon ),( Soo Yong Park ),( Min Young Rim ),( Hyeonsu Park ),( In Ku Yo ),( Oh Sang Kwon ),( Yun Soo Kim ),( Duck Jo 대한간학회 2013 춘·추계 학술대회 (KASL) Vol.2013 No.1
Background: Multi-antiviral drug resistance is a major problem in the treatment of patients with chronic hepatitis B (CHB). Tenofovir disoproxil fumarate (TDF) is recommended for ADV or entecavir (ETV). However, until recently TDF was not available in Korea. ADV and ETV combination therapy may be a viable alternative to TDF in patients with either ADV or ETV resistance. This study investigated the efficacy of ADV and ETV combination therapy in patients with multidrug resistance. Methods: Forty-one patients were enrolled and were administered ADV and ETV combination therapy for at least 12 months. Blood was drawn at baseline and at 12, 24, 36, 48, and 60 months after commencing treatment, and virological response was analyzed. Results: After ADV and ETV combination therapy, ALT normalization was 68%, 73%, 80% 90%, and 93% in 12wks, 24wks, 36wks, 48wks, and 60 wks, respectively. HBV DNA reduction was -1.5, -1.8, -1.9, -1.8, and -1.9 log10IU/mL in 12wks, 24wks, 36wks, 48wks, and 60 wks, respectively. 29 of HBeAg positive patients showed the following low HBeAg seroconversion rate: 3%, 7%, and 10% in 24wks, 48wks, and 60wks, respectively. In addition, virological response group showed lower initial HBV DNA level (P=0.014) and lower HBeAg positive rate (P=0.016) compared with non-virological response group. Conclusions: ADV and ETV combination therapy could be considered in selected chronic hepatitis B patients who have low initial HBV DNA level and HBeAg negative status.
Observation of melanoma cell Lines in phase contrast hard x-ray image using gold nanoparicles
( Soo Bin Son ),( Seung Han Ha ),( On Seok Lee ),( Gun Woo Lee ),( Jea Young Kim ),( Gyu Man Park ),( Sung Hee Moon ),( Sang Wook Son ),( Im Joo Rhyu ),( Sang Yeop Lee ),( Jae Bum Choo ),( Hwa Shik Yo 대한피부과학회 2008 초록집 Vol.46 No.20
A NEW INSTANTANEOUS VOLTAGE COMPENSATOR WITH FUNCTION OF ACTIVE POWER FILTERING
Seung-Yo Lee,Jeong-Min Lee,Sang-Yong Lee,Hyung-Soo Mok,Gyu-Ha Choe 전력전자학회 1998 ICPE(ISPE)논문집 Vol.- No.-
A novel active input unbalance voltage compensator with harmonic current compensating capability is proposed and the operating principle of the proposed system is presented in the 3-phase power system The proposed system performs both the voltage regulation of the load and the compensation of the harmonic currents generated due to nonlinear load such as diode rectifier The system to compensate unbalanced voltage and harmonic currents is composed of a 3-phase voltage source inverter, LC filter, series transformer and passive devices at the load side of the line. The compensating voltage to regulate the load voltage and to remove the harmonic current components is transmitted to the fine by the series transformer The validity of the proposed system is proved by the results of computer simulation.<br/>
( Soo Yong Park ),( Min Young Rim ),( In Ku Yo ),( Min Su Ha ),( Ju Seung Kim ),( Ju Won Lee ),( Young Kul Jung ),( Oh Sang Kwon ),( Yun Soo Kim ),( Duck Joo Choi ),( Ju Hyun Kim ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.-
Background: Combination therapy that includes both peginterferon and ribavirin is currently the worldwide standard therapy for chronic hepatitis C (CHC). Different therapeutic effects depending on different race have been reported, however, we do not yet have a big study conducted in Korea that could be used to compare with other country or race. Thus, the purpose of this study was to collect the studies that have been recently reported in Korea in order to analyze the therapeutic effect and compare it to that of other races from countries in Asia, Europe, and United States of America. Methods: Using PubMed and KoreaMed, papers published from 2006 to 2011 in Korea were searched and the papers were related to the therapeutic effect of combination therapy with peginterferon and ribavirin in patients with CHC in Korea. Eleven papers were selected for pooled analysis. The data from other part of Asia and western countries were searched through Pubmed and sixteen papers were selected for pooled analysis and comparison with Korean data. Results: The analysis for genotype 1 CHC in Korea showed that early virologic response (EVR), end of treatment response (ETR), sustained virologic response (SVR) were found to be 79.6% (125/157), 80.1% (166/207), and 62.7% (341/543) respectively. EVR, ETR, and SVR for genotype 2 and 3 were 89.4% (119/133), 92.2% (203/220), and 84.1% (434/516) respectively. In the Other asian countries data showed that EVR and SVR for genotype 1 were 51.3% (1981/3860) and 42.4% (1798/4231) respectively and 87.7% (350/399), and 77.8% (533/685) for genotype 2 and 3. In case of European and Caucasian, EVR and SVR for genotype 1 were 51.3% (1981/3860) and 42.4% (1798/4231) respectively, and that of genotype 2 and 3 were 87.7% (350/399) and 77.8% (533/685) respectively. Comparing between Korean data and the data of other races, there was no statistical difference in SVR of standard therapy for CHC (p=0.508), however, SVR of Koreans were higher than that of either Caucasians or Europeans (p≤ 0.001). On the other hand, there was no difference in SVR for genotype 2 CHC according to different races. Conclusions: SVR of combination therapy for the Korean CHC patients was similar to that of other Asian race but higher than that of European or Caucasian race. Therefore, Koreans respond well to combination therapy and this is thought to have its reason in genetic factor.
Seung Yun Kim,Hyoung Jin Lee,Eujin Park,Yo Han Ahn,Il-Soo Ha,Hae Il Cheong,강희경 대한소아신장학회 2015 Childhood kidney diseases Vol.19 No.2
Rituximab (RTX), a monoclonal antibody against the B-cell marker CD20, is commonly used as a treatment for antibody-mediated diseases or B-lymphocytemediated diseases. Destruction of B cells may reverse the disease course in many conditions; however, patients who are treated with RTX cannot respond appropriately to de novo infection due to lack of B lymphocytes. Here, we report one such case. A 7-year-old renal allograft recipient presented with severe anemia due to parvovirus infection after RTX treatment. The patient had focal segmental glomerulosclerosis and had received cadaveric kidney transplantation 6 months previously. She was treated with high-dose steroid for acute rejection and RTX for Epstein Barr Virus infection 3 months previously. At presentation, her hemoglobin level was 5.4 g/dL and leukocyte and platelet counts were normal. She had microcytic normochromic anemia and high viral load of parvovirus B19(70,578 copies/mL). Intravenous immunoglobulin (200 mg/kg·d) treatment controlled the progression of anemia and parvovirus infection. De novo parvovirus infection during the B lymphocyte-depletion period may have precipitated the severe anemia in this case. Close monitoring of infection is required after RTX therapy.
( Soo Yong Park ),( Min Young Rim ),( In Ku Yo ),( Min Su Ha Ju ),( Seung Kim ),( Ju Won Lee ),( Young Kul Jung ),( Oh Sang Kwon ),( Yun Soo Kim ),( Duck Joo Choi ),( Ju Hyun Kim ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1
Background: Combination therapy that includes both peginterferon and ribavirin is currently the worldwide standard therapy for chronic hepatitis C (CHC). Different therapeutic effects depending on different race have been reported, however, we do not yet have a big study conducted in Korea that could be used to compare with other country or race. Thus, the purpose of this study was to collect the studies that have been recently reported in Korea in order to analyze the therapeutic effect and compare it to that of other races from countries in Asia, Europe, and United States of America. Methods: Using PubMed and KoreaMed, papers published from 2006 to 2011 in Korea were searched and the papers were related to the therapeutic effect of combination therapy with peginterferon and ribavirin in patients with CHC in Korea. Eleven papers were selected for pooled analysis. The data from other part of Asia and western countries were searched through Pubmed and sixteen papers were selected for pooled analysis and comparison with Korean data. Results: The analysis for genotype 1 CHC in Korea showed that early virologic response (EVR), end of treatment response (ETR), sustained virologic response (SVR) were found to be 79.6% (125/157), 80.1% (166/207), and 62.7% (341/543) respectively. EVR, ETR, and SVR for genotype 2 and 3 were 89.4% (119/133), 92.2% (203/220), and 84.1% (434/516) respectively. In the Other asian countries data showed that EVR and SVR for genotype 1 were 51.3% (1981/3860) and 42.4% (1798/4231) respectively and 87.7% (350/399), and 77.8% (533/685) for genotype 2 and 3. In case of European and Caucasian, EVR and SVR for genotype 1 were 51.3% (1981/3860) and 42.4% (1798/4231) respectively, and that of genotype 2 and 3 were 87.7% (350/399) and 77.8% (533/685) respectively. Comparing between Korean data and the data of other races, there was no statistical difference in SVR of standard therapy for CHC (p=0.508), however, SVR of Koreans were higher than that of either Caucasians or Europeans (p≤ 0.001). On the other hand, there was no difference in SVR for genotype 2 CHC according to different races. Conclusions: SVR of combination therapy for the Korean CHC patients was similar to that of other Asian race but higher than that of European or Caucasian race. Therefore, Koreans respond well to combination therapy and this is thought to have its reason in genetic factor.